Abdel-Rhman El-Gazzar

Prof. Abdel-Rhman El-Gazzar


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 February 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAbdel-Rhman El-Gazzar
Abdel-Rhman El-Gazzar
MYM.M. Youssef
M.M. Youssef
AYA.M.S. Youssef
A.M.S. Youssef
Ameen A. Abu-HashemAmeen A. Abu-Hashem
Ameen A. Abu-Hashem
FBF.A. Badria
F.A. Badria


1 July 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AEAbdel-Rhman El-Gazzar
Abdel-Rhman El-Gazzar
HHHend Hafez
Hend Hafez

1 March 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AEAbdel-Rhman El-Gazzar
Abdel-Rhman El-Gazzar
MEMervat M. El-Enany
Mervat M. El-Enany
MMMahmoud N. Mahmoud
Mahmoud N. Mahmoud

1 January 2008 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
HHHend Hafez
Hend Hafez
HAHeba Abbas
Heba Abbas
AEAbdel-Rhman El-Gazzar
Abdel-Rhman El-Gazzar
New series of 2-hydrazino-7,8-dihydro-6H-cyclopenta[5,6] pyrido[2,3-d]pyrimidines and its 1,7,8,9-tetrahydrocyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine, 1,7,8,9-tetrahydrocyclopenta[5,6]pyrido[2,3-d][1,2,3,4]tetrazolo[4,5-a]pyrimidine, 8,9-dihydro-7H-cyclopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidine, 2-(pyrazol-1-yl)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidine derivatives were prepared in order to obtain new compounds with potential anti-inflammatory and analgesic activity and low ulcerogenic effect. The compounds possessing potent anti-inflammatory activity were further tested for their analgesic and ulcerogenic activities. Compounds 3-amino-6-(4-aryl)-9-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4c), 1-amino-2-methyl-6-(4-aryl)-9-(4-aryl-methylene)-cyclopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidin-5(H)-one (6a), 2-amino-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta[5,6]pyrido-[2,3-d]pyrimidine-4(H)-one (9), 2-(3-amino-5-hydroxypyrazol- 1-yl)-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta[5,6]-pyrido[2,3-d]pyrimidin-4(H)-one (10a) and 3-thioxo-6-(4-aryl)-9-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d]-[1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (13) showed significant analgesic effects. Compound 2-(3-amino-5-hydroxypyrazol-1-yl)-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta [5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10a) was evaluated as the lead compound having higher anti-inflammatory activity (82.8%) than ibuprofen (79.5%) and lower ulcerogenic effect.